Crigler-Najjar Syndrome Type 1: Key Concepts

Crigler-Najjar syndrome, particularly Type 1, is characterized by impaired bilirubin glucuronidation, leading to elevated unconjugated bilirubin and potential kernicterus. Diagnosis is suggested by pathological neonatal jaundice, normal conjugated bilirubin, and the absence of anemia, highlighting the importance of early detection and management to prevent neurological damage.

Impaired glucuronidation is the primary defect in Crigler-Najjar syndrome, resulting in the buildup of unconjugated bilirubin. Glucuronidation, normally performed by the UGT1A1 enzyme, is essential for making bilirubin water-soluble and excretable.

Elevated unconjugated bilirubin is a hallmark of Crigler-Najjar syndrome. This buildup occurs because the liver cannot effectively conjugate bilirubin, preventing its removal from the body.

Type 1 Crigler-Najjar syndrome is characterized by a complete or near-complete absence of UGT1A1 enzyme activity. This severe deficiency distinguishes it from Type 2, which has some residual enzyme activity.

Kernicterus is a major complication of Type 1 Crigler-Najjar syndrome, arising when high levels of unconjugated bilirubin cross the blood-brain barrier. Bilirubin's neurotoxicity can lead to permanent brain damage and even death if left untreated.

Normal conjugated bilirubin levels and absence of anemia, in the presence of pathological neonatal jaundice, are indicators pointing towards Crigler-Najjar syndrome. These factors help differentiate it from other causes of jaundice, such as hemolytic anemia or biliary obstruction.

Browse public study notes